Elanco Animal Health (NYSE:ELAN) Lowered to Buy Rating by Wall Street Zen

Wall Street Zen downgraded shares of Elanco Animal Health (NYSE:ELAN) from a strong-buy rating to a buy rating in a research note published on Saturday morning.

ELAN has been the topic of several other research reports. JPMorgan Chase & Co. boosted their price objective on Elanco Animal Health from $24.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, February 19th. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Friday, March 27th. KeyCorp boosted their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Finally, Leerink Partners boosted their target price on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $27.90.

Elanco Animal Health Stock Up 2.4%

ELAN stock opened at $23.68 on Friday. The stock’s fifty day simple moving average is $24.34 and its two-hundred day simple moving average is $23.12. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. Elanco Animal Health has a 1-year low of $8.33 and a 1-year high of $27.72. The stock has a market cap of $11.77 billion, a P/E ratio of -49.33, a P/E/G ratio of 2.95 and a beta of 1.88.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the previous year, the firm earned $0.14 earnings per share. The business’s revenue was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Analysts expect that Elanco Animal Health will post 0.91 EPS for the current year.

Institutional Trading of Elanco Animal Health

Several hedge funds have recently made changes to their positions in ELAN. UBS Group AG raised its stake in shares of Elanco Animal Health by 56.7% in the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after buying an additional 5,961,457 shares during the period. T. Rowe Price Investment Management Inc. raised its stake in shares of Elanco Animal Health by 11.8% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock valued at $797,197,000 after purchasing an additional 3,717,404 shares during the period. Invesco Ltd. raised its stake in shares of Elanco Animal Health by 336.0% during the 4th quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock valued at $108,376,000 after purchasing an additional 3,690,735 shares during the period. Artemis Investment Management LLP bought a new stake in shares of Elanco Animal Health during the 4th quarter valued at $55,693,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after purchasing an additional 2,445,872 shares during the period. 97.48% of the stock is currently owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.